INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03837509 · TERMINATED
Trial details
- NCT number
- NCT03837509
- Sponsor
- Incyte Corporation
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-25
- Primary completion
- 2022-04-05
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.